An open-label, single-dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cinacalcet in pediatric subjects aged 28 days to < 6 years with chronic kidney disease receiving dialysis

BACKGROUND: Calcimimetics, shown to control biochemical parameters of secondary hyperparathyroidism (SHPT), have well-established safety and pharmacokinetic profiles in adult end-stage renal disease subjects treated with dialysis; however, such studies are limited in pediatric subjects. METHODS: In...

Descripción completa

Detalles Bibliográficos
Autores principales: Sohn, Winnie Y., Portale, Anthony A., Salusky, Isidro B., Zhang, Hao, Yan, Lucy L., Ertik, Bella, Shahinfar, Shahnaz, Lee, Edward, Dehmel, Bastian, Warady, Bradley A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6244811/
https://www.ncbi.nlm.nih.gov/pubmed/30141180
http://dx.doi.org/10.1007/s00467-018-4054-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6244811/
https://www.ncbi.nlm.nih.gov/pubmed/30141180
http://dx.doi.org/10.1007/s00467-018-4054-8

Ejemplares similares